drugset / Trial / NCT07204964
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
Timeline
- Start
- 2025-10-07
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flu mRNA (Formulation B1) | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | Flu mRNA (Formulation B3) | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | Flu mRNA(Formulation A) | Messenger RNA (mRNA) | — | Intramuscular |